Testicular cancer gauge often underused
Serum-based tumor markers are not used in more than half of all patients who have testis cancer,
report researchers at the University of Michigan Comprehensive Cancer Center, Ann Arbor.
Archive for March, 2008
Targeted therapy extends progression-free survival in advanced RCC
An independent data monitoring committee stopped a major phase III clinical trial of the
investigational drug everolimus (RAD001) after interim results showed significantly better progression-free
survival in patients with advanced kidney cancer who received everolimus compared with placebo.
First-line bladder cancer therapy receives fast track designation
The FDA has indicated that a new therapy for first-line nonmuscle-invasive bladder cancer meets the
criteria for fast track designation.
New stem cell sources offer hope for wider clinical use
Research led by Anthony Atala, MD, has shown that non-embryonic sources of stem cells may lead to
safer, more effective clinical use.
Cystectomy over age 80: Patient selection is key
For very elderly patients with bladder cancer, good outcomes with radical cystectomy are possible
primarily through appropriate patient selection, timely surgical management, and meticulous postoperative
care.
Advances in kidney cancer therapy
Traditional immunotherapy for renal cell carcinoma (RCC) is being supplanted by new medications that
target the biology of kidney cancer. Based on demonstrated efficacy, 3 of these novel agents have now been approved
for advanced disease.
Male factor infertility, testicular cancer linked
Men with a history of infertility have a markedly increased risk of subsequently developing testicular
cancer.